Ontology highlight
ABSTRACT: Background
Approximately 30%-45% of patients with nondialysis CKD have iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or without anemia, there has not been a comprehensive approach to estimating the association between serum biomarkers of iron stores, and mortality and cardiovascular event risks.Methods
The study included 5145 patients from Brazil, France, the United States, and Germany enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study, with first available transferrin saturation (TSAT) and ferritin levels as exposure variables. We used Cox models to estimate hazard ratios (HRs) for all-cause mortality and major adverse cardiovascular events (MACE), with progressive adjustment for potentially confounding variables. We also used linear spline models to further evaluate functional forms of the exposure-outcome associations.Results
Compared with patients with a TSAT of 26%-35%, those with a TSAT ≤15% had the highest adjusted risks for all-cause mortality and MACE. Spline analysis found the lowest risk at TSAT 40% for all-cause mortality and MACE. Risk of all-cause mortality, but not MACE, was also elevated at TSAT ≥46%. Effect estimates were similar after adjustment for hemoglobin. For ferritin, no directional associations were apparent, except for elevated all-cause mortality at ferritin ≥300 ng/ml.Conclusions
Iron deficiency, as captured by TSAT, is associated with higher risk of all-cause mortality and MACE in patients with nondialysis CKD, with or without anemia. Interventional studies evaluating the effect on clinical outcomes of iron supplementation and therapies for alternative targets are needed to better inform strategies for administering exogenous iron.
SUBMITTER: Guedes M
PROVIDER: S-EPMC8455257 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
Guedes Murilo M Muenz Daniel G DG Zee Jarcy J Bieber Brian B Stengel Benedicte B Massy Ziad A ZA Mansencal Nicolas N Wong Michelle M Y MMY Charytan David M DM Reichel Helmut H Waechter Sandra S Pisoni Ronald L RL Robinson Bruce M BM Pecoits-Filho Roberto R
Journal of the American Society of Nephrology : JASN 20210708 8
<h4>Background</h4>Approximately 30%-45% of patients with nondialysis CKD have iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or without anemia, there has not been a comprehensive approach to estimating the association between serum biomarkers of iron stores, and mortality and cardiovascular event risks.<h4>Methods</h4>The study included 5145 patients from Brazil, France, the United States, and Germany enrolled in the Chronic Kidney Dise ...[more]